scispace - formally typeset
Journal ArticleDOI

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

TLDR
In patients with laryngeal cancer, radiotherapy with concurrent administration of cisplatin is superior to induction chemotherapy followed by radiotherapy or radiotherapy alone for larynGEal preservation and locoregional control.
Abstract
Background Induction chemotherapy with cisplatin plus fluorouracil followed by radiotherapy is the standard alternative to total laryngectomy for patients with locally advanced laryngeal cancer. The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown. Methods We randomly assigned patients with locally advanced cancer of the larynx to one of three treatments: induction cisplatin plus fluorouracil followed by radiotherapy, radiotherapy with concurrent administration of cisplatin, or radiotherapy alone. The primary end point was preservation of the larynx. Results A total of 547 patients were randomly assigned to one of the three study groups. The median follow-up period was 3.8 years. At two years, the proportion of patients who had an intact larynx after radiotherapy with concurrent cisplatin (88 percent) differed significantly from the proportions in the groups given induction chemotherapy followed by radiotherapy (75 percent, P=0.005) or radiotherapy alone (70 ...

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Swallowing dysfunction is a common sequelae after chemoradiation for oropharynx carcinoma.

TL;DR: The most notable difference in sequelae between the 2 groups was the increase in swallowing dysfunction with concurrent chemotherapy, which decreases the recurrence at the primary site and above the clavicles.
Journal ArticleDOI

Longitudinal oncology registry of head and neck carcinoma (LORHAN)

TL;DR: A study was undertaken to examine the patterns of systemic therapy use in conjunction with radiation therapy for patients with locally advanced head and neck squamous cell cancer.
Journal ArticleDOI

Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer.

TL;DR: The authors' purpose was to report efficacy and toxicity after weekly cisplatin (30 mg/m2/wk) concurrent with altered fractionation RT.
Journal ArticleDOI

Cisplatin versus Cetuximab Given Concurrently with Definitive Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

TL;DR: DSS was superior in the patients given cisplatin with definitiveRT compared to cetuximab with definitive RT due to a lower risk of recurrent disease in the cis platin group, and could not be explained by differences between the two groups in the patient and tumor characteristics or in treatment delivery.
Journal ArticleDOI

Treatment-Related Toxicities in Older Adults with Head and Neck Cancer: A Population-Based Analysis

TL;DR: Assessment of types and frequencies of toxicities in older adults with locally or regionally advanced head and neck squamous cell carcinoma who were receiving either primary CTRT or radiation therapy (RT) alone.
References
More filters
Book ChapterDOI

Nonparametric Estimation from Incomplete Observations

TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI

A Multiple Comparison Procedure for Comparing Several Treatments with a Control

TL;DR: In this article, a multiple comparison procedure for comparing several treatments with a control is presented, which is based on the Multiple Comparison Procedure for Comparing Several Treatments with a Control (MCPC).
Journal ArticleDOI

A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk

Robert Gray
- 01 Jan 1988 - 
TL;DR: In this paper, a class of tests developed for comparing the cumulative incidence of a particular type of failure among different groups is presented. The tests are based on comparing weighted averages of the hazards of the subdistribution for the failure type of interest.
Journal ArticleDOI

Cancer statistics, 2003.

TL;DR: The American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year, and compiles the most recent data on cancer incidence, mortality, and survival by using incidence data from the National Cancer Institute (NCI) and mortality data from National Center for Health Statistics (NCHS).
Related Papers (5)